Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Opiant Pharmaceuticals Inc (NQ: OPNT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 20.80 (24)
Ask (Size) 24.99 (1)
Prev. Close 20.65
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 4,399,675
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio
Indivior PLC (OTCPK:INVVY) (LSE:INDV) has completed the acquisition of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) The transaction strengthens Indivior's addiction treatment and science portfolio by... 
Via Benzinga
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
From Opiant Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

More News

Read More
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
From Opiant Pharmaceuticals, Inc.
Via GlobeNewswire
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
From Opiant Pharmaceuticals, Inc.
Via GlobeNewswire
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
From Kahn Swick & Foti, LLC
Via Business Wire
Analyzing Opiant Pharma's Short Interest
Via Benzinga
How Is The Market Feeling About Opiant Pharma?
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Tesla, Amazon, Opiant, Nu, Paramount: Lawsuit, Earnings, Warren Buffett's Increased Stake Draw Investor Attention
Via Benzinga
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. - OPNT
From Kahn Swick & Foti, LLC
Via Business Wire
Looking Into Opiant Pharma's Recent Short Interest
Via Benzinga
Dow Surges 150 Points; Crude Oil Falls Sharply
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Opiant Pharmaceuticals (NASDAQ: OPNT) Enters Into Definitive Agreement to be Acquired by Indivior for $145 Million
Via Spotlight Growth
Stocks Cool Off From Last Week's Rally
Via Talk Markets
Silver Rises Over 1%; Tyson Foods Posts Downbeat Earnings
Via Benzinga
Party City Layoffs 2022: What to Know About the PRTY Job Cuts
Via InvestorPlace
Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
Via InvestorPlace
US Stocks Mostly Lower; Nasdaq Drops Over 100 Points
Via Benzinga
OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Facebook Stalls Portal & Smartwatch Projects, Visa Breaks Debit Card Tie Up With FTX, $3B Bitcoin Withdrawn From Crypto Exchanges: Top Stories Monday, Nov. 14
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.